Creating Social Impact with Technology at Special Olympics

 
You probably watched the Olympics on television before, but have you had the chance to be part of a local Special Olympics event, which supports individuals with intellectual disabilities? If not, look into it; the Special Olympics helps 5.5 million athletes and takes more than 1 million volunteers to run the program in 193 different countries. This takes a massive amount of data to promote successful organization and efficiency.

How does The Special Olympics use information from millions of athletes to enhance the experience and improve involvement?

On today’s episode of DisruptED, Host Ronald Stefanski speaks with Prianka Nandy, Chief Information and Technology Officer of Special Olympics, to discuss how Nandy is helping the audience better plug into Special Olympics as a movement. During the pandemic, the Special Olympics saw reduced athlete numbers. Now, they are trying grow back by understanding who their athletes really are and how they can best be involved through one of many components of their research called “The Athlete Movement Project.”

Stefanski and Nandy also discussed…

How she has used data from 16 million athletes to continue her transformation journey at the Special Olympics

The different levels of engagement available at the Special Olympics

What else the Special Olympics has to offer to participants aside from the actual athletic experience

Nandy described how she hopes the data they are collecting will transform involvement. “We’ve been able to find talent, we’ve been able to find the corporate sponsorships in some cases and we’re starting to come through with a core centralized data strategy…so it’s not just about we want your money to help our organization. It’s about we want your time and your involvement and engagement. And how can we convert you, say, from a donor to a coach, or from an athlete to a coach?”

Nandy is Chief Information and Technology Officer of Special Olympics International and has experience designing digital and data governance structures. She has served in other international positions such as Chief Data and Analytics Officer and Data Program Manager, Technology Division, at World Food Programme. Nandy’s accolades include VPU Team Awards for the 2 Minute Feedback Survey, the Open Knowledge Repository, and the World Bank Finances Mobile App from the World Bank Group. She has a BA in Economics from Virginia Tech and a Master of Public Policy with a Social Policy concentration from George Mason University.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More